Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Neurocrine Biosciences, Inc.
Neurocrine Biosciences shares gained 12 percent on nearly five-times the average daily volume Tuesday. The company recently reported that it has been granted two additional patents related to its proprietary VMAT2 inhibitor. The company is scheduled to release its result for the fourth quarter on Friday, February 8th.
Going forward ... (see research report)
Subscribe to News Feeds